We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The agency cautioned that patients should not take the drug if they have a history of allergic reactions to human granulocyte colony-stimulating factors. Read More
The Noctiva manufacturer also criticized the subject population in Ferring’s clinical trial, stating that clinical trial enrollment for Noctiva NDAs should be restricted to patients aged 50 or older. Read More